09:53 AM EST - Medicenna Therapeutics Corp. : Announced today that, as planned and previously announced, new data from two of its preclinical programs were presented orally at the Promise of Interleukin-2 Conference held in Paris over the weekend. Medicenna Therapeutics Corp.
shares T.MDNA are trading up $0.03 at $2.25.
